John Kiely Sells 50,000 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director John Kiely sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $17.64, for a total transaction of $882,000.00. Following the completion of the sale, the director directly owned 210,252 shares of the company’s stock, valued at approximately $3,708,845.28. This trade represents a 19.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Amneal Pharmaceuticals Price Performance

NASDAQ AMRX opened at $18.15 on Friday. The business’s fifty day moving average price is $17.24 and its 200-day moving average price is $14.59. The stock has a market capitalization of $5.80 billion, a price-to-earnings ratio of 37.04 and a beta of 1.27. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. Amneal Pharmaceuticals, Inc. has a 1-year low of $9.20 and a 1-year high of $19.26.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Zacks Research upgraded shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. Weiss Ratings lowered shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday. Barclays upped their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. The Goldman Sachs Group reiterated a “buy” rating and set a $21.00 price target on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Finally, UBS Group boosted their price objective on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $17.67.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMRX. Rubric Capital Management LP boosted its position in shares of Amneal Pharmaceuticals by 5.3% in the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock worth $123,473,000 after purchasing an additional 624,609 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Amneal Pharmaceuticals by 1.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company’s stock valued at $70,723,000 after purchasing an additional 81,546 shares during the period. Morgan Stanley lifted its stake in shares of Amneal Pharmaceuticals by 37.5% during the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock valued at $60,708,000 after buying an additional 1,315,018 shares in the last quarter. Nantahala Capital Management LLC lifted its stake in shares of Amneal Pharmaceuticals by 14.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after buying an additional 558,877 shares in the last quarter. Finally, State Street Corp boosted its holdings in Amneal Pharmaceuticals by 3.4% in the 4th quarter. State Street Corp now owns 4,110,410 shares of the company’s stock worth $51,791,000 after buying an additional 136,662 shares during the period. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.